Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$8,342,352
-$31,342,963 QoQ
Shares Held
4,822,169
-17.3% QoQ
Ownership
7.20%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#4
of 60 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PERCEPTIVE ADVISORS LLC holds $5,486,611,234 across 68 Biotechnology names. ENGN ranks #54 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
2,035,986 | $681,627,752 | |
| 2 | SYRE |
Spyre Therapeutics, Inc.
|
4,319,496 | $383,484,854 | |
| 3 | CELC |
Celcuity Inc.
|
3,197,200 | $334,491,064 | |
| 4 | ASND |
Ascendis Pharma A/S
|
1,163,721 | $310,387,665 | |
| 5 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
2,586,295 | $287,156,333 | |
| 6 | ROIV |
Roivant Sciences Ltd.
|
8,085,461 | $286,144,464 | |
| 7 | RLAY |
Relay Therapeutics, Inc.
|
14,106,187 | $263,926,758 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
3,752,574 | $213,183,728 |
All Filings in ENGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,342,352 | 4,822,169 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $11,936,659 | 6,899,803 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $39,685,315 | 5,827,506 | Shares | Sole | 2026-05-29 | |
| 2025-12-31 | $52,997,756 | 5,869,076 | Shares | Sole | 2026-02-17 | |
| 2025-11-11 | $59,716,736 | 6,770,605 | Shares | Sole | 2025-11-18 | |
| 2025-09-30 | $14,324,121 | 2,097,236 | Shares | Sole | 2025-11-14 | |
| 2024-06-30 | $7,544,000 | 800,000 | Shares | Sole | 2024-08-16 | |
| 2024-03-31 | $16,931,151 | 998,888 | Shares | Sole | 2024-08-06 | |
| No filing history on record for this holder in this stock. | ||||||